99 Result(s)

Article

Subcutaneous Levodopa: A New Engine for the Vintage Molecule

The management of Parkinson’s disease (PD) continues to evolve with advancements in non-oral levodopa-based therapies aiming to provide continuous drug delivery (CDD). Such therapies address the challenges pos...

Karolina Poplawska-Domaszewicz, Lucia Batzu… in Neurology and Therapy (2024)

Article

Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease

The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson’s disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In th...

Anna Sauerbier, Johanna Herberg, Vasilija Stopic… in npj Parkinson's Disease (2024)

Article

Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

Apomorphine sublingual film (SL-APO) is an on-demand treatment for OFF episodes in patients with Parkinson’s disease (PD).

Jan Kassubek, Stewart A. Factor, Ernest Balaguer, Johannes Schwarz… in Journal of Neurology (2024)

Article

No evidence for an association of voxel-based morphometry with short-term non-motor outcomes in deep brain stimulation for Parkinson’s disease

Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy in advanced Parkinson’s disease (PD). Motor and non-motor outcomes, however, show considerable inter-individual variability...

Philipp Alexander Loehrer, Wibke Schumacher, Stefanie T. Jost… in npj Parkinson's Disease (2024)

Article

Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness Study

Parkinson’s disease is now one of the fastest-growing neurodegenerative disorders in the developed world, with an increasing prevalence and associated socioeconomic costs. Progression of the disease leads to a...

K. Ray Chaudhuri, Jean-Philippe Azulay, Per Odin… in Drugs - Real World Outcomes (2024)

Article

The PD-Ballet study: study protocol for a randomised controlled single-blind hybrid type 2 clinical trial evaluating the effects of ballet dancing on motor and non-motor symptoms in Parkinson’s disease

To date, beneficial effects of multimodal exercise programmes on Parkinson’s disease (PD) have focused on motor symptoms and little attention has been paid to the potential effects of such programmes on the no...

Aleksandra M. Podlewska, Lucia Batzu… in BMC Complementary Medicine and Therapies (2024)

Article

A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable perio...

Vinod Metta, Huzaifa Ibrahim, Neha Muralidharan… in Journal of Neural Transmission (2024)

Article

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin… in Neurology and Therapy (2023)

Article

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) wi...

Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin… in Neurology and Therapy (2023)

Article

Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease

Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopami...

P. Tall, M. A. Qamar, L. Batzu, V. Leta… in Journal of Neural Transmission (2023)

Article

Grey-matter correlates of empathy in 4-Repeat Tauopathies

Loss of empathy is an early and central symptom of frontotemporal lobar degeneration spectrum diseases. We aimed to investigate the topographical distribution of morphometric brain changes associated with empa...

Benedetta Tafuri, Daniele Urso, Salvatore Nigro… in npj Parkinson's Disease (2023)

Article

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone

To evaluate the long-term, real-life effects on non-motor symptoms (NMS) of opicapone compared to entacapone in levodopa-treated people with Parkinson’s disease (PwP).

Valentina Leta, Daniel J. van Wamelen, Federico Aureli… in Journal of Neural Transmission (2023)

Article

Author Correction: Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?

M. A. Qamar, A. Sauerbier, M. Politis, H. Carr, P. A. Loehrer… in npj Parkinson's Disease (2023)

Article

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis

Research comparing levodopa/carbidopa intestinal gel (LCIG), deep brain stimulation (DBS), and continuous subcutaneous apomorphine infusion (CSAI) for advanced Parkinson’s disease (PD) is lacking. This network...

Angelo Antonini, Rajesh Pahwa, Per Odin, Stuart H. Isaacson, Aristide Merola… in CNS Drugs (2022)

Article

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease

Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at amino...

Lucia Batzu, Silvia Rota, Abdul Hye, Amanda Heslegrave… in npj Parkinson's Disease (2022)

Article

Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?

Continuous drug delivery (CDD) is used in moderately advanced and late-stage Parkinson’s disease (PD) to control motor and non-motor fluctuations (‘OFF’ periods). Transdermal rotigotine is indicated for early ...

Silvia Rota, Daniele Urso, Daniel J. van Wamelen… in Translational Neurodegeneration (2022)

Article

Implications of dopaminergic medication withdrawal in Parkinson’s disease

The trajectory of the use of dopamine replacement therapy (DRT) in Parkinson’s disease (PD) is variable and doses may need to be increased, but also tapered. The plan for dose adjustment is usually done as per...

J. Koschel, K. Ray Chaudhuri, L. Tönges, M. Thiel… in Journal of Neural Transmission (2022)

Article

Viruses, parkinsonism and Parkinson’s disease: the past, present and future

Parkinsonism secondary to viral infections is not an uncommon occurrence and has been brought under the spotlight with the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A va...

Valentina Leta, Daniele Urso, Lucia Batzu, Yue Hui Lau… in Journal of Neural Transmission (2022)

Article

Clinical trajectories and biomarkers for weight variability in early Parkinson’s disease

Unexplained weight changes that occur in Parkinson’s disease (PD), are often neglected and remain a poorly understood non-motor feature in patients with PD. A specific ‘Park-weight’ phenotype with low body wei...

Daniele Urso, Daniel J. van Wamelen, Lucia Batzu, Valentina Leta… in npj Parkinson's Disease (2022)